NCT06750159Not yet recruiting
The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma
Clinical Study of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 27 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Based on the clue that the serum marker AKR1B10 found in the investigators' previous study can be used as an effective indicator for detecting HCC and preHCC, the role and value of AKR1B10 as a new tumor marker for evaluating the recurrence monitoring of HCC after radical surgical resection needs further study, as to provide detailed clinical research data and scientific basis for improving the survival rate of HCC patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 12 Dec 2024
- Start date
- 16 Dec 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06750159
What you commit to
- Study type: Observational
- Planned participants: 400
- From 16 Dec 2024 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Complicated with serious heart, brain, lung, kidney, hematopoietic and other system diseases.
Other
- Patients who are pregnant or nursing.
- Patients with incomplete clinical data, serological and imaging findings.
- Patients who were lost to follow-up before the observation endpoint.
Who the study is looking for
- Meets the diagnostic criteria of primary hepatocellular carcinoma.
- Meet the criteria for radical resection of hepatocellular carcinoma.
- No anti-cancer treatment before the first diagnosis.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.